vorinostat has been researched along with osimertinib in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 4 (80.00) | 2.80 |
| Authors | Studies |
|---|---|
| Duan, G; Liu, T; Wan, Y; Xia, C; Xiao, Y | 1 |
| Chen, J; Kuang, P; Peng, X; Sun, Z | 1 |
| Abuo-Rahma, GEA; Badr, M; Bass, AKA; El-Zoghbi, MS; Mohamed, MFA; Nageeb, EM | 1 |
| Chu, B; Ding, C; Fan, T; Jiang, Y; Shi, Z; Sun, Q; Tan, C; Yuan, Z; Zhang, C; Zhao, L | 1 |
| Arai, S; Fukuda, K; Ong, ST; Roca, X; Takeuchi, S; Tanimoto, A; Yamada, T; Yano, S | 1 |
3 review(s) available for vorinostat and osimertinib
| Article | Year |
|---|---|
Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy.
Topics: Antineoplastic Agents; DNA Damage; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Neoplasms; Protein Kinases; Proteins; Structure-Activity Relationship; Topoisomerase Inhibitors | 2020 |
Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Molecular Structure; Neoplasms | 2020 |
Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
Topics: Androgen Antagonists; Animals; Antineoplastic Agents; Benzimidazoles; Cyclic Nucleotide Phosphodiesterases, Type 5; Daunorubicin; Doxorubicin; fms-Like Tyrosine Kinase 3; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Molecular Targeted Therapy; Morpholines; Nicotinamide Phosphoribosyltransferase; Nitric Oxide; Pyrimidines; Quinazolines; Structure-Activity Relationship; Transcription Factors | 2021 |
2 other study(ies) available for vorinostat and osimertinib
| Article | Year |
|---|---|
Design, synthesis and evaluation of novel ErbB/HDAC multitargeted inhibitors with selectivity in EGFR
Topics: Antineoplastic Agents; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Molecular Docking Simulation; Molecular Structure; Mutation; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship | 2021 |
Histone Deacetylase 3 Inhibition Overcomes
Topics: Acrylamides; Aniline Compounds; Apoptosis; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Piperazines; Protein Kinase Inhibitors; Sequence Deletion; Vorinostat | 2017 |